Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 39,211 | 47,072 | 78,592 | 46,826 | 72,832 |
| Gross Profit | 39,211 | 47,072 | 78,592 | 46,826 | 72,832 |
| Operating Expenses | 388,610 | 308,707 | 244,122 | 208,082 | 173,362 |
| Operating Income | -349,399 | -261,635 | -165,530 | -161,256 | -100,530 |
| Interest Expense | 370 | 249 | 196 | 176 | 175 |
| Other Income | 38,418 | 38,026 | 18,764 | 6,624 | 488 |
| Pre-tax Income | -311,351 | -223,858 | -146,962 | -154,808 | -100,217 |
| Net Income Continuous | -311,351 | -223,858 | -146,962 | -154,808 | -100,217 |
| Net Income | $-311,351 | $-223,858 | $-146,962 | $-154,808 | $-100,217 |
| EPS Basic Total Ops | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 |
| EPS Basic Continuous Ops | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 |
| EPS Diluted Total Ops | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 |
| EPS Diluted Continuous Ops | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 |
| EPS Diluted Before Non-Recurring Items | N/A | -2.98 | -2.52 | -2.87 | -2.09 |
| EBITDA(a) | $-349,965 | $-268,245 | $-167,194 | $-157,390 | $-92,326 |